New study aims to predict lung damage from cancer treatments before It's too late

NCT ID NCT07190703

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks for early warning signs of lung injury caused by cancer drugs. Researchers will analyze blood and lung fluid samples from 200 patients using advanced techniques to find biomarkers that could predict or detect this side effect early. The goal is to help doctors identify at-risk patients sooner and improve treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a blood or fluid test that catches lung damage from cancer drugs early, helping doctors adjust treatment sooner.

What could go wrong

This is an observational study, not testing a treatment. It is early-stage research, and the biomarkers may not prove reliable in real-world use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-TUMOR DRUG-ASSOCIATED INTERSTITIAL PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

drug or radiation exposure-related interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••